Glycopyrrolate
Glycopyrrolate is a quaternary ammonium compound that is fully ionized, which significantly limits its ability to cross the placenta. Due to its poor lipid solubility and ionization, glycopyrrolate demonstrates very limited placental transfer (UV/MV ratio well under 0.2), ensuring minimal fetal exposure; in practice fetal heart rate does not change after a maternal dose.
Fetal Effect: Given its limited transfer across the placenta, glycopyrrolate does not pose any significant risks to the fetus. It is often used in obstetric anesthesia to manage maternal conditions such as excessive salivation or bradycardia without concern for fetal exposure. The lack of significant placental transfer makes glycopyrrolate a safe and effective option for use alongside other drugs during labor, with no risk of fetal side effects.
Atropine
Atropine, in contrast to glycopyrrolate, is a lipid-soluble tertiary amine that crosses the placenta easily. Its ability to penetrate biological membranes results in nearly complete placental transfer (UV/MV ratio about 0.9 within 5 minutes of an intravenous dose), making it an effective drug for managing maternal bradycardia or for other obstetric indications, but also increasing the potential for fetal exposure.
Fetal Effect: Due to its nearly complete placental transfer, atropine can cause fetal tachycardia and other autonomic effects if administered in higher doses. While these effects are typically transient, they can include elevated fetal heart rate and loss of beat-to-beat (short-term) variability on the fetal heart rate tracing, which can be mistaken for fetal compromise if the team does not know the drug was given. Careful monitoring of both maternal and fetal heart rates is necessary when atropine is administered, particularly in higher doses, to minimize any potential adverse effects on the fetus.
Neostigmine
Neostigmine is a quaternary ammonium compound widely used to reverse non-depolarizing neuromuscular blockade during anesthesia. Despite its ionized nature, neostigmine (a smaller molecule, about 223 Da, versus about 398 Da for glycopyrrolate) crosses the placenta more rapidly than other ionized drugs like glycopyrrolate. This makes it effective in its clinical use but also poses potential risks to the fetus when administered during pregnancy, since the cholinergic effect it produces in the fetus (bradycardia) is not opposed unless an anticholinergic also reaches the fetus.
Fetal Effect: When neostigmine is used in conjunction with glycopyrrolate, the combination has been associated with fetal bradycardia. This is thought to occur due to glycopyrrolate’s limited ability to cross the placenta, leaving neostigmine’s effects unopposed. To avoid this complication, the recommendation in obstetric anesthesia is to use atropine instead of glycopyrrolate when administering neostigmine for neuromuscular blockade reversal. Atropine crosses the placenta more readily, preventing the unopposed cholinergic effects that lead to bradycardia. The pairing is neostigmine 0.04 to 0.07 mg/kg with atropine 0.01 to 0.02 mg/kg, and it applies only when a fetus is still in utero: for reversal after a cesarean delivery, once the baby is out, glycopyrrolate is used as usual because its lower maternal heart-rate and secretion effects are then the only consideration.
| Agent | Extent of placental transfer | Fetal consequence |
|---|---|---|
| Succinylcholine | Very slow and minimal; small molecule but fully ionized, poorly lipid soluble and hydrolyzed within minutes by maternal plasma cholinesterase; undetectable in cord blood after a standard dose | No meaningful effect on neonatal muscle function or respiratory capacity (exceptions: massive or repeated doses, a neonate homozygous for atypical cholinesterase) |
| Rocuronium, vecuronium, atracurium, cisatracurium | Slow and minimal; bulky, highly ionized quaternary ammonium compounds with poor lipid solubility (UV/MV about 0.07 to 0.16) | No significant neonatal depression, muscle weakness or apnea after usual doses; transient hypotonia possible after prolonged or repeated dosing |
| Sugammadex | Very large (about 2,178 Da), highly polar; expected to cross very little, but data in pregnancy are limited | No fetal effect described; SOAP (2019) advises against routine use before delivery, reserving it for airway rescue |
| Glycopyrrolate | Very limited (UV/MV well under 0.2); fully ionized quaternary ammonium compound with poor lipid solubility | No significant fetal risk; fetal heart rate unchanged |
| Neostigmine | Crosses more rapidly than other ionized drugs despite being a quaternary ammonium compound | Fetal bradycardia when given with glycopyrrolate, as its cholinergic effect goes unopposed |
| Atropine | Nearly complete transfer (UV/MV about 0.9 within 5 minutes); lipid-soluble tertiary amine | Fetal tachycardia and loss of beat-to-beat variability at higher doses, usually transient |
| Benzodiazepines (midazolam, diazepam) | Rapid and nearly complete; highly lipid soluble and unionized at physiologic pH (midazolam UV/MV about 0.7, diazepam above 1 within minutes) | Neonatal sedation, respiratory depression, hypotonia, decreased responsiveness and poor respiratory effort after repeated or large doses or diazepam; a single small midazolam dose at induction has not been shown to depress the neonate |
